瑞康醫藥(002589.SZ)擬通過增資擴股方式獲得樂康金嶽79.8%股權
格隆匯 1 月 26日丨瑞康醫藥(002589.SZ)公佈,公司於2021年1月26日召開第四屆董事會第十一次會議審議通過了《關於向關聯方控制的山東樂康金嶽實業有限公司增資暨關聯交易的議案》,同意公司簽署《關於山東樂康金嶽實業有限公司之增資協議書》,公司擬通過增資擴股的方式獲得山東樂康金嶽實業有限公司(“樂康金嶽”)79.8%的股權,投資金額為3.2億元人民幣。
樂康金嶽一期建設項目已竣工,根據瑞康醫藥總體發展戰略,十四五將着重在大健康領域方面搭建平台,此次增資控股樂康金嶽後,樂康金嶽已建成的辦公及運營場所可為上市公司提供辦公及經營場地,同時徹底解決關聯交易問題。
瑞康醫藥已儲備了部分擬引入項目,其中與阿斯利康合作的創新中心也選址在樂康金嶽建成的健康產業園內,將設置展示中心、共創空間、加速器等多個模塊,推動診療一體化項目在山東省內的覆蓋。後續瑞康醫藥將陸續實施的項目體量較大,有擴大業務規模的現實需求,樂康金嶽具有符合瑞康醫藥未來產業方向所需的產業園,對瑞康醫藥後期的產業拓展具有支撐作用,此次增資控股樂康金嶽,有利於樂康金嶽後期的產業導入和拓展,同時也解決了上市公司與控股股東因業務可能產生的同業競爭問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.